Experimental immune therapy targets stubborn blood cancers
NCT ID NCT06705530
Summary
This study tested a personalized immune therapy called CAR-T for adults with B-cell blood cancers that returned or didn't respond to standard treatments. Researchers collected immune cells from patients, engineered them in a lab to better target cancer, then infused them back. The main goals were to check safety, see how well patients tolerated the treatment, and measure if it helped control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Medical Research Center for Hematology
Moscow, 125167, Russia
Conditions
Explore the condition pages connected to this study.